alexa Clinicopathological And Prognostic Value Of Programmed Death Ligand-1 (PD-L1) In Breast Cancer: A Meta-analysis
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Breast Cancer
May 08-10, 2017 Singapore

Guochao Zhang, Xue Qi, Likun Huang
Chinese Academy of Medical Sciences and Peking Union Medical College, China
Shanxi Provincial People’s hospital, China
Posters & Accepted Abstracts: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-003
Background: Programmed death ligand-1 (PD-L1) is an immunological checkpoint protein that has recently been found to be associated with the prognosis of various malignancies. However, the association between PD-L1 expression and the survival of breast cancer patients has remained unclear. Therefore, the aim of the present meta-analysis was to assess the clinical value of PD-L1 in breast cancer patients. Methods: MEDLINE/PubMed, EMBASE, Cochrane Library, and Grey Literature databases were searched up to 30 March 2016 for articles involving an association between PD-L1 expression and breast cancer prognosis. Hazard ratios for overall survival with 95% confidence intervals (CIs) according to the expression status of PD-L1 were calculated. Odds ratios (ORs) were also analyzed to evaluate the association between clinicopathological parameters and PD-L1 expression. Results: Ten studies were included in this meta-analysis and 7 of these described clinicopathological features. Elevated levels of PDL1 were only significantly associated with histological grade (OR = 1.86, 95% CI: 1.38–2.51; Pheterogeneity = 0.0196), estrogen receptor status (ER) (OR = 0.36, 95% CI: 0.17–0.75; Pheterogeneity = 0.000), and progesterone receptor status (PR) (OR = 0.31, 95% CI: 0.11–0.86; Pheterogeneity = 0.000). Conclusion: There were trends observed in the present meta-analysis, although PD-L1 status as a predictor of prognosis for patients with breast cancer could not be confirmed. Therefore, further studies of mechanism(s) related to PD-L1 expression level and immune escape and antitumor immune responses are needed, especially in relation to breast cancer subtypes. Furthermore, an evaluation standard for PD-L1 expression would facilitate all future studies.

Zhang Guochao is working as a resident for the second year in Peking Union Medical College and Hospital at present.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version